Literature DB >> 21135181

Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.

Robin L P Jump1, Yuejin Li, Michael J Pultz, Georgios Kypriotakis, Curtis J Donskey.   

Abstract

Tigecycline is a broad-spectrum glycylcycline antibiotic with potent in vitro activity against Clostridium difficile. We used a mouse model to test the hypothesis that tigecycline has a low propensity to promote colonization and toxin production by C. difficile due to inhibitory activity in the colon. Mice (5 to 8 per group) received subcutaneous injections of tigecycline (low and high doses) alone or in combination with clindamycin for 6 days. Growth of and toxin production by 3 strains of C. difficile (tigecycline MICs ≤ 0.012 μg/ml) were measured in cecal contents collected 6 h or 3 days after the final antibiotic dose. Antibiotic concentrations were measured using a bioassay, and concentrations of total anaerobes and Bacteroides spp. were measured. The effects of tigecycline on rendering mice susceptible to colonization with and reducing the burden of C. difficile were also examined. In comparison to saline controls, clindamycin promoted the growth of C. difficile (P < 0.001) in cecal contents, whereas tigecycline did not. Tigecycline did not suppress total anaerobes or Bacteroides spp. in comparison to saline controls. Concurrent administration of tigecycline prevented clindamycin-induced promotion of C. difficile in cecal contents collected 6 h or 3 days (high dose only) after the final antibiotic dose. Tigecycline did not promote the establishment of colonization in mice, yet it did not reduce concentrations of C. difficile in animals with established colonization. In summary, tigecycline did not promote the growth of or toxin production by C. difficile, probably due to inhibitory activity against C. difficile and relative sparing of indigenous anaerobic microflora.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135181      PMCID: PMC3028805          DOI: 10.1128/AAC.00839-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Faecal concentrations of piperacillin and tazobactam in elderly patients.

Authors:  M H Wilcox; A Brown; J Freeman
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

2.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.

Authors:  Bjorn L Herpers; Bart Vlaminckx; Olaf Burkhardt; Harmjo Blom; Hazra S Biemond-Moeniralam; Mathias Hornef; Tobias Welte; Edward J Kuijper
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

5.  Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

Authors:  Simon D Baines; Katie Saxton; Jane Freeman; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2006-10-08       Impact factor: 5.790

6.  Effective and reduced-cost modified selective medium for isolation of Clostridium difficile.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

Review 7.  Antimicrobial-associated risk factors for Clostridium difficile infection.

Authors:  Robert C Owens; Curtis J Donskey; Robert P Gaynes; Vivian G Loo; Carlene A Muto
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.

Authors:  Daniel A Adams; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

9.  Evidence for low risk of Clostridium difficile infection associated with tigecycline.

Authors:  M H Wilcox
Journal:  Clin Microbiol Infect       Date:  2007-08-13       Impact factor: 8.067

10.  Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.

Authors:  Mark H Wilcox; Jane Freeman; Warren Fawley; Sarah MacKinlay; Alex Brown; Katrina Donaldson; Oliver Corrado
Journal:  J Antimicrob Chemother       Date:  2004-05-26       Impact factor: 5.790

View more
  22 in total

1.  Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.

Authors:  Hyeun Bum Kim; Quanshun Zhang; Xingmin Sun; Gillian Beamer; Yuankai Wang; Saul Tzipori
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 2.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 3.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

4.  Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 5.  Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Gut Microbes       Date:  2013-12-11

6.  The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Authors:  Angela E Reeves; Casey M Theriot; Ingrid L Bergin; Gary B Huffnagle; Patrick D Schloss; Vincent B Young
Journal:  Gut Microbes       Date:  2011-05-01

7.  Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.

Authors:  Casey M Theriot; Charles C Koumpouras; Paul E Carlson; Ingrid I Bergin; David M Aronoff; Vincent B Young
Journal:  Gut Microbes       Date:  2011-11-01

Review 8.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

Review 9.  Clostridium difficile and the microbiota.

Authors:  Anna M Seekatz; Vincent B Young
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

10.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.